Protein Kinase Inhibitors: all 15,147 studies that test it

Page 130 of 152. Open to participants first (2,533), then studies with results posted, then the rest; newest registration first within each.

• A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic CancerCompletedNCT01335269Phase 1
• Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced MalignanciesCompletedNCT01335256Phase 1
• Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)WithdrawnNCT01335074Phase 1/2
• Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell LymphomaCompletedNCT01334502Phase 1
• Study of Axitinib in Patients With Unresectable Hepatocellular CarcinomaCompletedNCT01334112Phase 2
• Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid TumorsCompletedNCT01334073Phase 1
• Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)WithdrawnNCT01333423Phase 1
• Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by SurgeryCompletedNCT01333085Phase 1/2
• Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation TherapyWithdrawnNCT01332279Phase 1
• Aflac ST0901 CHOANOME - Sirolimus in Solid TumorsCompletedNCT01331135Phase 1
• 24-hour Efficacy of AR-12286CompletedNCT01330979Phase 2
• A Study to Compare Two Different Tablet Formulations of AZD8931 in Healthy Males and FemalesCompletedNCT01330758Phase 1
• Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal MelanomaWithdrawnNCT01328106Phase 2
• Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine TumorCompletedNCT01324492Phase 1
• Study of INC280 in Patients With c-MET Dependent Advanced Solid TumorsCompletedNCT01324479Phase 1
• Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid TumorsCompletedNCT01324258Phase 1
• Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By SurgeryStatus unknownNCT01324076Phase 3
• Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)CompletedNCT01323400Phase 2
• PD0332991/Paclitaxel in Advanced Breast CancerCompletedNCT01320592Phase 1
• Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung CancerSuspendedNCT01320501Phase 4
• BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate CancerTerminatedNCT01320280Phase 2
• Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line TreatmentCompletedNCT01320111Phase 2
• Effect of Ketoconazole on Regorafenib (BAY73-4506) PharmacokineticsCompletedNCT01318265Phase 1
• A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy SubjectsCompletedNCT01316848Phase 1
• A Study of ARRY-382 in Patients With Selected Advanced or Metastatic CancersCompletedNCT01316822Phase 1
• AZD8055 for Adults With Recurrent GliomasCompletedNCT01316809Phase 1
• Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell CancerCompletedNCT01316757Phase 2
• Glivec in Prostate Cancer Patients With Rising PSA Following Radical ProstectomyCompletedNCT01316458Phase 2
• Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous LeukemiaCompletedNCT01316250Not applicable
• Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck CancerTerminatedNCT01313390Phase 1/2
• De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab InductionTerminatedNCT01312064Phase 4
• Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy SubjectsCompletedNCT01311622Phase 1
• Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic LeukemiaCompletedNCT01310010Phase 2
• Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy SubjectsCompletedNCT01309854Phase 1
• Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)CompletedNCT01309633Phase 2
• Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb®) in Patients With ErbB2-Positive Stage I-III Breast CancerStatus unknownNCT01309607Phase 2
• Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant RadiotherapyCompletedNCT01308034Phase 1
• A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid TumorsCompletedNCT01306630Phase 1
• Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant RecipientsWithdrawnNCT01305395Not applicable
• A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive CancerCompletedNCT01304784Phase 1
• A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal CancerCompletedNCT01304602Phase 1
• Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or MelanomaActive, not recruitingNCT01303341Phase 1
• Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic CancerCompletedNCT01303029Phase 2
• AR-12286 in Combination With LatanoprostCompletedNCT01302249Phase 2
• Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast CancerCompletedNCT01300962Phase 1
• Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid TumorsCompletedNCT01300468Phase 1
• AMG 319 Lymphoid Malignancy FIHCompletedNCT01300026Phase 1
• Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic CancerCompletedNCT01298713Phase 2
• Imatinib in KIT-negative Systemic MastocytosisCompletedNCT01297777Phase 4
• BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid TumorsCompletedNCT01297452Phase 1
• Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue SarcomaWithdrawnNCT01296659Phase 1
• Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)CompletedNCT01295632Phase 1
• A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GISTCompletedNCT01294202Phase 2
• Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal CancerStatus unknownNCT01291823Phase 2
• BEZ235 Trial in Patients With Advanced Endometrial CarcinomaWithdrawnNCT01290406Phase 2
• Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast CancerCompletedNCT01290354Phase 1
• Studying the Effect of Changing Immunosuppression in Case of Polyoma BK Virus Infection of the Renal TransplantStatus unknownNCT01289301Phase 4
• BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast CancerWithdrawnNCT01288092Phase 2
• Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung CancerStatus unknownNCT01287962Phase 3
• A Study of LY2875358 in Participants With Advanced CancerCompletedNCT01287546Phase 1
• AZD6244 With Cetuximab for Solid Tumors and Colorectal CancerCompletedNCT01287130Phase 1
• A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the TabletCompletedNCT01287091Phase 1
• A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.TerminatedNCT01286974Phase 1
• Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid TumorsCompletedNCT01286896Phase 1
• A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without TrastuzumabCompletedNCT01285466Phase 1
• A Study of LY2801653 in Advanced CancerCompletedNCT01285037Phase 1
• Healthy Volunteers, Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] AZD8931CompletedNCT01284595Phase 1
• Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)CompletedNCT01284192Phase 1
• Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid TumorsCompletedNCT01283945Phase 1/2
• Lapatinib and RAD-001 for HER2 Positive Metastatic Breast CancerStatus unknownNCT01283789Phase 2
• A Study of BKM120 in Adult Japanese Patients With Advanced Solid TumorsCompletedNCT01283503Phase 1
• Midostaurin (PKC412) for Locally Advanced Rectal CancerCompletedNCT01282502Phase 1
• Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular CancerWithdrawnNCT01281943Phase 2
• A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic CancerCompletedNCT01281514Phase 1
• Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast CancerTerminatedNCT01281163Phase 1
• Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-KitTerminatedNCT01280565Phase 3
• A Safety Study of Oral ZSTK474 in Patients With CancerCompletedNCT01280487Phase 1
• Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)CompletedNCT01279473Phase 1/2
• First-in-Human Single Ascending and Multiple Dose of GLPG0778CompletedNCT01278108Phase 1
• Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal TransplantationTerminatedNCT01276834Phase 4
• Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female SubjectsCompletedNCT01276262Phase 1
• Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain MetastasesCompletedNCT01276210Phase 1
• Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast CancerCompletedNCT01275859Phase 2
• Axitinib as Second-line Treatment for Advanced Hepatocellular CarcinomaCompletedNCT01273662Phase 2
• Palomid 529 in Patients With Neovascular Age-Related Macular DegenerationCompletedNCT01271270Phase 1
• Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal CancerTerminatedNCT01271166Phase 1
• Safety of CHIR-258 (TKI258) in Advanced Solid TumorsTerminatedNCT01270906Phase 1
• Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)WithdrawnNCT01270893Phase 2
• Whole Soy and Daidzein on Reduction of Blood Pressure in Postmenopausal Chinese WomenStatus unknownNCT01270737Not applicable
• A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung CancerCompletedNCT01270386Phase 2
• Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant RecipientsWithdrawnNCT01269684Phase 4
• Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal TumorCompletedNCT01267695Phase 2
• An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian CancerCompletedNCT01266954Phase 1
• Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)CompletedNCT01266837Phase 4
• Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V MutationCompletedNCT01266369Phase 2
• Sirolimus or Vorinostat and Hydroxychloroquine in Advanced CancerCompletedNCT01266057Phase 1
• Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell CarcinomaTerminatedNCT01264341Phase 2
• Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib AloneStatus unknownNCT01263951Phase 2
• A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid MalignanciesCompletedNCT01263899Phase 2
• MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast CancerCompletedNCT01263145Phase 1

← Protein Kinase Inhibitors overview